| 前收市價 | 27.96 |
| 開市 | 27.96 |
| 買盤 | 21.40 |
| 賣出價 | 22.10 |
| 拍板 | 87.50 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 27.96 - 27.96 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 133 |
- Insider Monkey
12 Safe Stocks to Buy For Long-Term
In this article, we take a look at 12 safe stocks to buy for the long-term according to hedge funds. You can skip our detailed analysis of safe stocks and go directly to read 5 Safe Stocks to Buy According to Hedge Funds. Even if there are many indications that the macro environment will remain […]
- Benzinga
Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients
Merck & Co Inc's (NYSE: MRK) Phase 3 NRG-GY018 trial evaluating Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS). The trial covered patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status. Related: Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients. The treatment regime included Keytruda + Chemo combo, then continued
- Benzinga
Merck's Oral COVID-19 Treatment Might Be Linked To Spreading Mutations, Study Shows
According to some researchers, Merck & Co’s (NYSE: MRK) COVID-pill is giving rise to new mutations of the COVID-19 virus in some patients. Mutations linked to Merck’s COVID-19 oral treatment Lagevrio (Molnupiravir) have been identified in viral samples taken from several patients, according to a preprint study from researchers in the U.S. and at the Francis Crick Institute, Imperial College London, and other U.K. institutions. Also Read: Merck Beats On Q4 earnings, Anticipates Almost 80% Decline
